Table 4.
Cost-effectiveness of other cancer therapies in NSCLC in China
| Drug | Control arm | Study perspective | ICER, US$ per QALY | Indication |
|---|---|---|---|---|
| Osimertinib [44] | Chemotherapy | Payer and the healthcare system | 48,081 | NSCLC after progression following first-line EGFR TKI therapy |
| Gefitinib [40] |
Pemetrexed plus cisplatin alone |
Chinese healthcare system | 28,485 | First-line treatments for aNSCLC |
| Gefitinib strategy with PAP [40] | Pemetrexed plus cisplatin alone | Chinese healthcare system | 22,577 | First-line treatments for aNSCLC |
| Icotinib [40] | Pemetrexed plus cisplatin alone | Chinese healthcare system | 19,809 | First-line treatments for aNSCLC |
| Bevacizumab [45] | Pemetrexed plus cisplatin | Social perspective | 299,155 | Maintenance therapy for metastatic NSCLC |
| Nivolumab versus docetaxel in the present analysis for comparison | ||||
| Nivolumab | Docetaxel | Healthcare payer in China | 33,802a | Squamous |
| Nivolumab | Docetaxel | Healthcare payer in China | 25,204a | Non-squamous |
aConversion using exchange rate ¥1 = US$0.148487; May 3, 2019; www.xe.com
aNSCLC advanced non-small cell lung cancer, EGFR epidermal growth factor receptor, ICER incremental cost-effectiveness ratio, NSCLC non-small cell lung cancer, PAP patient assistance programme, QALY quality-adjusted life-year, TKI tyrosine kinase inhibitor